A recent study led by researchers at the University of Arizona Cancer Center and Northern Arizona University found that Native American women were disproportionately affected by vaginal dysbiosis, a disruption in the balance of bacterial that increases the risk of human papillomavirus infection, which can cause cervical cancer.
Fertility treatment increases the odds of ovarian cancer but not breast, endometrial, or cervical cancer, according to the results of an umbrella review published in Fertility and Sterility.
Personalis, Inc., in collaboration with professor Charles Swanton and his colleagues at London’s Francis Crick Institute and University College London, published new results from their TRACERx lung cancer study in Nature Medicine.
Two new studies led by researchers at Washington University School of Medicine in St. Louis have identified a possible way to block the progression of several forms of blood cancer using a drug already in clinical trials against breast cancer.
A recent population-based study indicates that among children with cancer, those with obesity at the time of diagnosis may face an elevated risk of dying. The findings are published by Wiley online in CANCER.
UC Davis Comprehensive Cancer Center researcher Sanchita Bhatnagar and her team have been working to get to the bottom of the genetic determinants of the racial disparity in triple-negative breast cancer.
Scientists at City of Hope identified a protein that could help prevent CAR T-cell therapy antigen escape. The research, published in the journal Cell, could lead to more personalized therapies that improve cancer patients’ survival.
A little-known mouse protein disrupts cancer-causing chemical changes to genes associated with human colorectal cancer cells and potentially could be used to treat solid tumors, according to a new study from researchers at the Johns Hopkins Kimmel Cancer Center and the Chinese Academy of Sciences.
FDA approved sotorasib (Lumakras) with panitumumab (Vectibix) for adult patients with KRAS G12C-mutated metastatic colorectal cancer, as determined by an FDA-approved test, who have received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.
FDA approved acalabrutinib (Calquence) with bendamustine and rituximab for adults with previously untreated mantle cell lymphoma who are ineligible for autologous hematopoietic stem cell transplantation.
